Salud financiera de hoja de balance de Moderna

Salud financiera controles de criterios 6/6

Moderna tiene un patrimonio de accionistas total de $19.1B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $25.9B y $6.7B respectivamente. El BAIT de Moderna es de $9.4B, por lo que su ratio de cobertura de intereses es de -55.1. Tiene efectivo e inversiones a corto plazo que ascienden a $9.9B.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	-55.1x
Efectivo	US$9.90b
Patrimonio	US$19.12b
Total pasivo	US$6.74b
Activos totales	US$25.86b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($13.4B) de 0QF superan a sus pasivos a corto plazo ($4.9B).

Pasivo a largo plazo: Los activos a corto plazo de 0QF ($13.4B) superan a sus pasivos a largo plazo ($1.8B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 0QF está libre de deudas.

Reducción de la deuda: 0QF no tenía deudas hace 5 años.

Cobertura de la deuda: 0QF no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: 0QF no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de Moderna

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Moderna Announces Update on Investigational Rsv Vaccine

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Investor sentiment improved over the past week

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Moderna, Inc. Announces Executive Changes

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Third quarter 2022 earnings released: EPS: US$2.67 (vs US$8.25 in 3Q 2021)

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Investor sentiment improved over the past week

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union

Moderna, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Moderna, Inc. Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Investor sentiment improved over the past week

Moderna, Inc. Announces Management Changes

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EMA Committee for Medicinal Products for Human Use (Chmp) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Moderna, Inc. Announces Swissmedic Authorizes its Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Moderna, Inc. Announces Executive Changes

Moderna, Inc. Announces Medicines and Healthcare Products Regulatory Agency Authorizes Omicron-Containing Bivalent Booster in the Uk

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera